CDEK
← All drugs Report issue

leronlimab

mAbexperimentalCOVID-19

Leronlimab is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer and HIV infection. — Wikipedia

Clinical trial activity

11 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
10
Phase 3
2
Phase 4
0

Earliest trial started Apr 22, 2019 (NCT03838367)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2021

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06699836Phase 2Feb 28, 2025CytoDyn, Inc., Syneos Health
NCT05730673Phase 2Sep 20, 2022Amarex Clinical Research, CytoDyn, Inc.
NCT04901689Phase 3Oct 23, 2021Albert Einstein Israelite Hospital, CytoDyn, Inc.
NCT04901676Phase 3Sep 9, 2021Albert Einstein Israelite Hospital, CytoDyn, Inc.
NCT04678830Phase 2Jan 21, 2021Amarex Clinical Research, CytoDyn, Inc.
NCT04521114Phase 2Oct 1, 2020Amarex Clinical Research, CytoDyn, Inc.
NCT04504942Phase 2May 1, 2020Amarex Clinical Research, CytoDyn, Inc.
NCT04347239Phase 2Apr 15, 2020CytoDyn, Inc.
NCT04343651Phase 2Apr 1, 2020CytoDyn, Inc.
NCT03838367Phase 1/Phase 2 (Phase 2)Apr 22, 2019Amarex Clinical Research, CytoDyn, Inc.
NCT04313075N/A—CytoDyn, Inc.
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CytoDyn, Inc.For profit11932019
Amarex Clinical ResearchFor profit5012019
Albert Einstein Israelite HospitalAcademic/Hospital2212021
Syneos HealthFor profit1012025
4 organizations
Page 1 / 1